SynthesisDermatologic therapy2021
Management of urticaria in COVID-19 patients: A systematic review.
Synthesis in Dermatologic therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Management of urticaria in COVID-19 patients: A systematic review.Dermatologic therapy · 2021Pooled it
- Persistence, chronicity, and recurrence of infection-associated urticaria following viral infections in children and adults: a systematic review.Frontiers in allergy · 2026Review
- Vasculitis syndromes: the pathogenic roles of COVID-19 and related vaccinations.Virology journal · 2025Review
- Late-Onset Urticarial and Erythema Multiforme-Like Eruption Following SARS-CoV-2 Infection.Cureus · 2025Article
- Risk Factors for Psoriasis Flares: A Narrative Review.Psoriasis (Auckland, N.Z.) · 2024Review
- Cholinergic Urticaria After COVID-19 Infection.The American journal of medicine · 2023Article
- COVID-19 and cutaneous manifestations: A review of the published literature.Journal of cosmetic dermatology · 2023Review
- Pathobiology of Cutaneous Manifestations Associated with COVID-19 and Their Management.Viruses · 2022Review
- Urticarial rash as the initial presentation of COVID-19 infection: A case report.Clinical case reports · 2022Article
- The Impact of COVID-19 Pandemic on Dermatological Conditions: A Novel, Comprehensive Review.Dermatopathology (Basel, Switzerland) · 2022Review
- Recommendations for the recognition, diagnosis, and management of long COVID.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022Article
- Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Review
- Cutaneous Manifestations of SARS-CoV-2 Infection.American journal of clinical dermatology · 2022Review
- Experience with Cutaneous Manifestations in COVID-19 Patients during the Pandemic.Journal of clinical medicine · 2022Article
- Perinatal/maternal-fetal-infant dermatologic manifestations of SARS-CoV-2. An Overview and Implications for diagnosis, treatment, and prognosis.Frontiers in pediatrics · 2022Review
- Cervical and preauricular lymphadenopathies as atypical manifestations in the setting of COVID-19: a case report.Future virology · 2022Article
- Article
- Article
- Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.Journal of medical virology · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global pandemic COVID-19 has resulted in significant global morbidity, mortality and increased healthcare demands. There is now emerging evidence of patients experiencing urticaria. We sought to systematically review current evidence, critique the literature, and present our findings. Allowing PRISMA guidelines, a comprehensive literature search was carried out with Medline, EMBASE, Scopus, Cochrane, and Google Scholar, using key MeSH words, which include "COVID-19," "Coronavirus," "SARS-Cov-2," "Urticaria," "Angioedema," and "Skin rash" up to 01 August 2020. The key inclusion criteria were articles that reported on urticaria and/or angioedema due to COVID-19 infection and reported management and outcome. Studies were excluded if no case or cohort outcomes were observed. Our search returned 169 articles, 25 of which met inclusion criteria. All studies were case reports, reporting 26 patients with urticaria and/or angioedema, COVID-19 infection and their management and/or response. ajority of patients (n = 16, 69%) were over 50 years old. However, urticaria in the younger ages was not uncommon, with reported case of 2 months old infant. Skin lesions resolved from less than 24 hours to up to 2 weeks following treatment with antihistamines and/or steroids. There have been no cases of recurrent urticaria or cases nonresponsive to steroids. Management of urticarial in COVID-19 patients should involve antihistamines. Low dose prednisolone should be considered on an individualized basis. Further research is required in understanding urticarial pathogenesis in COVID-19. This will aid early diagnostic assessment in patients with high index of suspicion and subsequent management in the acute phase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.